8-K - MAIA Biotechnology, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

MAIA Biotechnology, Inc. disclosed the presentation of a clinical trial poster at the European Lung Cancer Congress 2026 on March 27, 2026, which was also posted to the company's website and filed as an exhibit. The poster contains forward-looking statements regarding the THIO-101 trial.

Key Takeaways

1A poster titled 'Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation in Abstract NSCLC Relapsed-Patients Treated with Ateganosine and ICI in the THIO-101 Trial' was prepared.

2The poster was presented at the European Lung Cancer Congress 2026 (ELCC) in Copenhagen, Denmark, on March 27, 2026.

3The poster was posted to the Company's website on March 27, 2026.

4A copy of the poster is filed as Exhibit 99.1 to this Current Report on Form 8-K.

5The poster contains forward-looking statements.

Current Report Details

Event Type

Regulation Fd

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

Regulation FD Disclosure. MAIA Biotechnology, Inc., (the “Company”) has prepared a poster (the “Poster”) entitled “Sustained Response and Long-Term Therapeutic

Regulation Fd

8.01

Other Events Reference is made to the disclosure under Item 7.01 above which is hereby incorporated in this Item 8.01 by reference. Item 9.01 Financial Statemen

Other Event

Exhibits (2)

8-K

99.1

EX-99.1